Every material Form 8-K Boston Scientific has filed with the SEC since September 04, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Boston Scientific Corporation announced its third quarter 2026 financial results, reporting net sales of $5.138 billion, a 1.5 percent increase compared to the prior year period. GAAP net income attributable to common stockholders was $582 million, or $0.40 per share, while adjusted EPS reached $0.73.
Generated third quarter 2026 net sales of $5.138 billion, up 1.5 percent reported, operational, and organic year-over-year.
Reported GAAP net income attributable to common stockholders of $582 million, or $0.40 per share, and adjusted EPS of $0.73.
Estimated full-year 2026 organic net sales growth of approximately 3.75 percent and adjusted EPS of $3.16 to $3.18.
Boston Scientific said Joe Fitzgerald, currently executive vice president and group president of Cardiovascular, will become executive vice president and chief operating officer effective January 1, 2027. The company also plans three new reportable segments effective the same date, and it named Mark Bickel as chief accounting officer effective March 1, 2027, succeeding Emily Woodworth.
Fitzgerald's offer letter sets an annual base salary of $1,050,000 and a bonus target of 110% of base salary.
His 2027 annual equity award has a total grant date fair value of $7,000,000, expected in February 2027.
Three reportable segments take effect January 1, 2027: Interventional Therapies, Rhythm Solutions and MedSurg.
Mark Bickel, 49, will become Senior Vice President, Global Accounting Controller and Chief Accounting Officer on March 1, 2027.
Boston Scientific said Executive Vice President and Group President Arthur C. Butcher will retire from his role on January 1, 2027, and remain as a senior advisor through February 26, 2027. The filing says the company expects a retirement agreement with payments and benefits materially consistent with his existing plan terms.
Butcher informed the company of his retirement decision on September 21, 2026.
He leads MedSurg and Asia Pacific as Group President; retirement is effective January 1, 2027.
As senior advisor, his current annual base salary is $780,000, prorated through the Retirement Date.
The Retirement Date is February 26, 2027, or any earlier date.
Boston Scientific said a cybersecurity incident identified on August 25, 2026 caused a global disruption to its operations, including manufacturing, order processing and shipping. The company believes the incident is likely to materially affect its third quarter and full year 2026 results, and it is unlikely to meet the net sales growth and adjusted EPS guidance it gave on July 29, 2026. The filing does not quantify the financial impact, and the company says the full effects are not yet known.
Incident identified August 25, 2026; the company activated incident response protocols with third-party cybersecurity experts.
Company is unlikely to meet previously provided net sales growth and adjusted EPS guidance for Q3 and full year 2026 (guidance issued July 29, 2026).
Major distribution centers are processing and shipping at or above normal levels, and manufacturing has resumed across most facilities; full recovery timing is uncertain.
Updated outlook for the rest of 2026 is expected on the Q3 earnings call on Wednesday, October 28, 2026; the company does not expect a material long-term impact on its financial condition.
Boston Scientific reported second quarter 2026 net sales of $5.442 billion, up 7.5% on a reported basis, and GAAP EPS of $0.61, up from $0.53 a year earlier. Adjusted EPS of $0.86 was above the company's $0.82 to $0.84 guidance range, and the company now expects full-year 2026 adjusted EPS of $3.28 to $3.32 and third-quarter adjusted EPS of $0.80 to $0.82. Shareholders should note a $76 million litigation-related charge in the quarter and a $1.5 billion investment in MiRus LLC.
Net sales of $5.442 billion, up 7.5% reported and 7.0% organic, at the top of the 5.5% to 7.5% reported guidance range
GAAP net income attributable to common stockholders of $907 million, or $0.61 per share, versus $797 million, or $0.53 per share, a year ago
Full-year 2026 guidance: reported net sales growth of 5.5% to 6.5% and adjusted EPS of $3.28 to $3.32; third-quarter adjusted EPS of $0.80 to $0.82
Completed a $2 billion accelerated share repurchase of about 40 million shares and invested $1.5 billion in MiRus LLC for an approximately 34% equity stake
On July 21, 2026, Boston Scientific's board approved a new global restructuring program with estimated total pre-tax charges of $700 million to $800 million, of which $600 million to $700 million is expected to be cash outlays. The company expects the plan to reduce gross annual pre-tax expenses by about $500 million, with a substantial portion reinvested in growth, and it expects some headcount reductions.
Board approved the 2026 Restructuring Plan on July 21, 2026; activities start in 2026 and are expected to be substantially complete by the end of 2029.
Estimated total pre-tax charges of $700 million to $800 million, including $600 million to $700 million in future cash outlays.
Charges by type: transfer costs $300 million to $350 million, termination benefits $275 million to $300 million, and other costs $125 million to $150 million.
Expected reduction in gross annual pre-tax expenses of about $500 million as program benefits are realized.
Boston Scientific reported first quarter 2026 net sales of $5.203 billion, up 11.6% on a reported basis and 9.4% on an organic basis from $4.663 billion a year earlier. GAAP diluted EPS was $0.90, versus $0.45, and adjusted EPS was $0.80, versus $0.75, with the adjusted figure at the top of the company's $0.78 to $0.80 guidance range. The company also issued updated 2026 outlook figures, including adjusted EPS of $3.34 to $3.41 for the full year and $0.82 to $0.84 for the second quarter.
Net sales of $5.203 billion rose 11.6% reported and 9.4% organic; Cardiovascular grew 13.5% and MedSurg grew 7.8%.
GAAP diluted EPS was $0.90 versus $0.45; the filing's reconciliation shows a $320 million deferred tax benefit excluded from adjusted results.
Adjusted EPS was $0.80 versus $0.75 a year ago and within the $0.78 to $0.80 guidance range.
Updated outlook: full-year 2026 reported net sales growth of 7.0% to 8.5% and adjusted EPS of $3.34 to $3.41; second-quarter adjusted EPS of $0.82 to $0.84.
On February 26, 2026, Boston Scientific entered three new credit agreements with Wells Fargo as administrative agent and terminated its 2021 revolving credit agreement. The $6.000 billion term loan may be drawn only to fund the pending acquisition of Penumbra, Inc., under a merger agreement dated January 14, 2026, which means the company will take on substantial new debt if the deal closes.
$3.000 billion 2026 Revolving Credit Agreement matures February 26, 2031, with a Maximum Leverage Ratio of 3.75x
$2.000 billion 364-day revolving credit agreement, with a ticking fee accruing 120 days after its effective date
$6.000 billion term loan: $1.000 billion Tranche A and $5.000 billion Tranche B, drawable only at the Penumbra acquisition closing
Prior 2021 revolving credit agreement, as amended through May 10, 2024, was terminated
Boston Scientific expanded its board from ten to twelve members and appointed Catherine R. Smith and Christophe P. Weber as directors, effective February 18, 2026. The board also approved a $4.0 billion increase to its stock repurchase authorization, bringing the total available to $5.0 billion, all of which remained available as of the filing date.
Board increased from ten to twelve members on February 18, 2026; Catherine R. Smith and Christophe P. Weber appointed directors effective that date.
Smith joins the Audit and Nominating and Governance committees; Weber joins the Executive Compensation and Human Resources and Risk, Science and Technology committees, effective February 23, 2026.
On February 18, 2026, the board approved an additional $4.0 billion repurchase authorization, for a total of $5.0 billion.
Each new director will receive prorated annual compensation, including a cash retainer of about $24,663 and an equity award of about $42,420, with shares granted March 2, 2026.
Boston Scientific said director Yoshiaki Fujimori, a board member since July 2016 who chairs the Risk, Science and Technology Committee, will not seek re-election at the 2026 Annual Meeting of Stockholders. He will remain a director and in his committee roles until that meeting, and the company said his decision is not the result of any disagreement. The filing does not name a replacement and says the board will continue to evaluate whether adding directors is in the company's best interest.
Yoshiaki Fujimori informed the company on February 2, 2026 that he will not stand for re-election.
He has served on the board since July 2016 and chairs the Risk, Science and Technology Committee.
He remains a director until the 2026 Annual Meeting of Stockholders.
The company states the decision was not the result of any disagreement.
Boston Scientific reported fourth-quarter 2025 net sales of $5.286 billion, up 15.9 percent from a year earlier, and adjusted EPS of $0.80, above its $0.77 to $0.79 guidance range. GAAP EPS was $0.45, below its $0.48 to $0.52 guidance range, after a $194 million litigation-related net charge. The company also estimated 2026 adjusted EPS of $3.43 to $3.49.
Q4 net sales of $5.286 billion, up 15.9 percent reported and 12.7 percent organic, versus guidance of 14.5 to 16.5 percent reported.
GAAP EPS of $0.45 versus $0.38 a year earlier and guidance of $0.48 to $0.52; adjusted EPS of $0.80 versus $0.70 a year earlier.
Litigation-related net charges of $194 million in the fourth quarter.
2026 guidance: reported net sales growth of 10.5 to 11.5 percent and adjusted EPS of $3.43 to $3.49.
On January 14, 2026, Boston Scientific entered a Merger Agreement under which Penumbra will merge into a Boston Scientific subsidiary and become a wholly owned subsidiary. Penumbra stockholders can elect $374.00 in cash or 3.8721 Boston Scientific shares per share, subject to proration that sets 73.26% of shares for cash and 26.74% for stock. Completion depends on Penumbra stockholder approval, antitrust and other regulatory clearances, and other conditions, and the filing excerpt ends before the full termination terms are described.
Cash election: $374.00 per Penumbra share; stock election: 3.8721 Boston Scientific shares per Penumbra share
Proration: 73.26% of Penumbra shares receive cash and 26.74% receive Boston Scientific stock
Penumbra equity awards: $274.00 in cash plus 1.0353 Boston Scientific shares, measured against a 10-day average trading price
Penumbra would pay Boston Scientific a $525,000,000 termination fee in specified circumstances
Boston Scientific's Board approved its 2026 Annual Bonus Plan and two 2026 performance share programs on November 18, 2025, covering the performance period from January 1, 2026 through December 31, 2028. The filing describes compensation terms for employees and executives, including payout ranges tied to sales, earnings and total shareholder return, but it does not report any financial results or new financial figures.
Board approved the 2026 Annual Bonus Plan on November 18, 2025, for the performance year January 1 to December 31, 2026.
Bonus pool payouts are set by the Compensation Committee at 0% to 150% of target, based on global sales, adjusted EPS, operating income and sustainability goals.
Two performance share programs cover January 1, 2026 to December 31, 2028, with awards of 0% to 200% of target based on relative total shareholder return and organic net sales growth.
Boston Scientific director John E. Sununu told the company on October 22, 2025, that he will not stand for re-election at the 2026 Annual Meeting of Stockholders. He will remain a director and keep his committee roles until that meeting, and the company says the decision is not the result of any disagreement.
Sununu has served on the Board since April 2009.
He currently sits on the Audit Committee and chairs the Nominating and Governance Committee.
He will continue as a director until the 2026 Annual Meeting.
The Board will evaluate whether to add directors after his departure.
Boston Scientific reported third-quarter 2025 net sales of $5.065 billion, up 20.3% on a reported basis and 15.3% on an organic basis from a year earlier. GAAP EPS was $0.51 and adjusted EPS was $0.75, both above the company's prior guidance ranges. The company also gave fourth-quarter and full-year 2025 guidance, estimating full-year reported net sales growth of about 20%.
Q3 reported net sales of $5.065 billion, up 20.3%, versus guidance of 17% to 19%
GAAP EPS of $0.51 versus guidance of $0.44 to $0.46; adjusted EPS of $0.75 versus guidance of $0.70 to $0.72
Q4 2025 guidance: reported net sales growth of 14.5% to 16.5%; GAAP EPS of $0.48 to $0.52; adjusted EPS of $0.77 to $0.79
Company discontinued worldwide sales of the ACURATE neo2 and ACURATE Prime Aortic Valve Systems in Q2 2025, which had prior year global sales of about $50 million per quarter
Boston Scientific said Executive Vice President and President of Peripheral Interventions Jeffrey B. Mirviss will retire from that role effective December 1, 2025, and will then serve as a senior advisor through February 27, 2026. The company expects to sign a retirement agreement with him with payments and benefits materially consistent with existing plans, which matters to shareholders mainly as a routine leadership transition in one business unit.
Mirviss informed the company of his retirement decision on August 29, 2025.
Retirement from his executive role takes effect December 1, 2025.
He will stay on as a senior advisor until the Retirement Date, no later than February 27, 2026, at his current $705,000 annual base salary, prorated.
A Retirement Agreement is expected, with terms materially consistent with existing executive retirement, bonus and long-term incentive plans.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Boston Scientific filing is on SEC EDGAR ↗. 8-K briefs of other companies →